The delivery of plasmid DNA-encoding IκBα shRNA and a melanoma-associated antigen tyrosinase-related protein-2 (TRP2) into skin-resident DCs via intradermal injection and electroporation can further enhance TRP2-specific cytotoxic activity, delay tumor growth in a melanoma subcutaneous tumor, and reduce the number of lung melanoma foci in mice injected intravenously with melanoma [80]. The gene discussed is DCT; the disease is neoplasm.